Jazz Pharmaceuticals plc (JAZZ), Thursday announced that Zanidatamab-hrii, marketed as Ziihera 50 mg/ml, for injection for intravenous use got the recommendation from the National Comprehensive Cancer Network or NCCN Clinical Practice Guidelines in oncology as a category 2A treatment option for biliary tract cancers or BTC.
Ziihera is a bispecific antibody approved for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) BTC.
The biopharma added that the recommendation reaffirmed Ziihera in the treatment of biliary tract cancer.
Currently, Jazz's stock is trading at $122.25, down 0.98 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.